Company
Hikma Pharmaceuticals plc
Headquarters: London, United Kingdom
Founded: 1978
Employees: 8,700
CEO: Mr. Sigurdur Oli Olafsson Ph.D.
Market Cap
£4.03 Billion
GBP as of July 1, 2024
US$5.10 Billion
Hikma Pharmaceuticals plc Categories
United Kingdom Healthcare Drug Manufacturers—Specialty & GenericUnited Kingdom Healthcare United Kingdom Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Hikma Pharmaceuticals plc has the following listings and related stock indices.
Stock: LSE: HIK wb_incandescent
Stock: FSX: H5P wb_incandescent
Product & Services
AmoclanPrografSuprax
Key People
Founder(s): Samih Darwazah
Said Darwazah (chairperson) Siggi Olafsson (CEO)
Financials
Revenue: US$2,553 million (2021)
Operating income: US$632 million (2021)
Net income: US$420 million (2021)